Last reviewed · How we verify

Tevimbra (TISLELIZUMAB)

Beigene · FDA-approved approved Monoclonal antibody Quality 50/100

Tevimbra (generic name: TISLELIZUMAB) is a Programmed Death Receptor-1 Blocking Antibody [EPC] Monoclonal antibody drug developed by Beigene. It is currently FDA-approved (first approved 2025) for Esophageal Cancer, Gastric Cancer, Esophageal Squamous Cell Carcinoma.

Tevimbra blocks the PD-1 receptor, allowing the immune system to recognize and attack cancer cells.

Tevimbra (tislelizumab) is a monoclonal antibody developed by Beigene that targets the PD-1 receptor, a protein that helps cancer cells evade the immune system. It works by blocking the PD-1 receptor, allowing the immune system to recognize and attack cancer cells. Tevimbra is approved to treat various types of esophageal and gastric cancers, including unresectable or metastatic esophageal squamous cell carcinoma and unresectable or metastatic HER2-negative gastric or gastroesophageal junction adenocarcinoma. Tevimbra is a patented product owned by Beigene, with no generic manufacturers listed. Key safety considerations include potential immune-mediated adverse reactions.

At a glance

Generic nameTISLELIZUMAB
SponsorBeigene
Drug classProgrammed Death Receptor-1 Blocking Antibody [EPC]
TargetPd-1
ModalityMonoclonal antibody
Therapeutic areaOncology
PhaseFDA-approved
First approval2025
Annual revenue900

Mechanism of action

Binding of the PD-1 ligands PD-L1 and PD-L2, to the PD-1 receptor found on T cells, inhibits T-cell proliferation and cytokine production. Upregulation of PD-1 ligands occurs in some tumors and signaling through this pathway can contribute to inhibition of active T-cell immune surveillance of tumors. Tislelizumab-jsgr binds to PD-1 and blocks its interaction with PD-L1 and PD-L2, releasing PD-1 pathway-mediated inhibition of the immune response, including the anti-tumor immune response. Tislelizumab-jsgr decreased tumor growth in xenograft models and a human PD-1 transgenic mouse model.

Approved indications

Common side effects

Key clinical trials

Patents

PatentExpiryType
Biologic Exclusivity

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

SourceUsed for
FDA labelMechanism, indications, dosing, boxed warnings, drug interactions
ClinicalTrials.govTrial enrolment, design, endpoints, results
FDA Orange BookPatents + exclusivity
SEC EDGARRevenue + earnings

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

Frequently asked questions about Tevimbra

What is Tevimbra?

Tevimbra (TISLELIZUMAB) is a Programmed Death Receptor-1 Blocking Antibody [EPC] drug developed by Beigene, indicated for Esophageal Cancer, Gastric Cancer, Esophageal Squamous Cell Carcinoma.

How does Tevimbra work?

Tevimbra blocks the PD-1 receptor, allowing the immune system to recognize and attack cancer cells.

What is Tevimbra used for?

Tevimbra is indicated for Esophageal Cancer, Gastric Cancer, Esophageal Squamous Cell Carcinoma, Gastric or gastroesophageal junction adenocarcinoma, Unresectable or metastatic esophageal squamous cell carcinoma.

Who makes Tevimbra?

Tevimbra is developed and marketed by Beigene (see full Beigene pipeline at /company/beigene).

What is the generic name of Tevimbra?

TISLELIZUMAB is the generic (nonproprietary) name of Tevimbra.

What drug class is Tevimbra in?

Tevimbra belongs to the Programmed Death Receptor-1 Blocking Antibody [EPC] class. See all Programmed Death Receptor-1 Blocking Antibody [EPC] drugs at /class/programmed-death-receptor-1-blocking-antibody-epc.

When was Tevimbra approved?

Tevimbra was first approved on 2025.

What development phase is Tevimbra in?

Tevimbra is FDA-approved (marketed).

What are the side effects of Tevimbra?

Common side effects of Tevimbra include Fatigue, Decreased Appetite, Anemia, Diarrhea, Stomatitis, Vomiting.

What is Tevimbra's annual revenue?

Tevimbra generated approximately $0.0B in annual revenue.

What does Tevimbra target?

Tevimbra targets Pd-1 and is a Programmed Death Receptor-1 Blocking Antibody [EPC].

Related